Lantus up last week, but new scrips fall

In the wake of new safety concerns about the drug, total U.S. prescription volume for the Sanofi-Aventis diabetes drug Lantus inched up 2 percent last week versus the week before, but new prescriptions were down 3.8 percent, according to a drug-data provider. Report

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.